Klümper, Niklas ; Ralser, Damian J. ; Ellinger, Jörg 
; Roghmann, Florian ; Albrecht, Julia ; Below, Eduard ; Alajati, Abdullah ; Sikic, Danijel ; Breyer, Johannes ; Bolenz, Christian ; Zengerling, Friedemann ; Erben, Philipp ; Schwamborn, Kristina ; Wirtz, Ralph M. ; Horn, Thomas ; Nagy, Dora ; Toma, Marieta ; Kristiansen, Glen ; Büttner, Thomas ; Hahn, Oliver ; Grünwald, Viktor ; Darr, Christopher ; Erne, Eva ; Rausch, Steffen ; Bedke, Jens ; Schlack, Katrin ; Abbas, Mahmoud ; Zschäbitz, Stefanie ; Schwab, Constantin ; Mustea, Alexander ; Adam, Patrick ; Manseck, Andreas ; Wullich, Bernd ; Ritter, Manuel ; Hartmann, Arndt ; Gschwend, Jürgen ; Weichert, Wilko ; Erlmeier, Franziska ; Hölzel, Michael ; Eckstein, Markus
; Roghmann, Florian ; Albrecht, Julia ; Below, Eduard ; Alajati, Abdullah ; Sikic, Danijel ; Breyer, Johannes ; Bolenz, Christian ; Zengerling, Friedemann ; Erben, Philipp ; Schwamborn, Kristina ; Wirtz, Ralph M. ; Horn, Thomas ; Nagy, Dora ; Toma, Marieta ; Kristiansen, Glen ; Büttner, Thomas ; Hahn, Oliver ; Grünwald, Viktor ; Darr, Christopher ; Erne, Eva ; Rausch, Steffen ; Bedke, Jens ; Schlack, Katrin ; Abbas, Mahmoud ; Zschäbitz, Stefanie ; Schwab, Constantin ; Mustea, Alexander ; Adam, Patrick ; Manseck, Andreas ; Wullich, Bernd ; Ritter, Manuel ; Hartmann, Arndt ; Gschwend, Jürgen ; Weichert, Wilko ; Erlmeier, Franziska ; Hölzel, Michael ; Eckstein, Markus 
Zusammenfassung
Purpose: The antibody-drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients with metastatic urothelial carcinoma (mUC) without prior assessment of the tumor receptor status as ubiquitous NECTIN-4 expression is assumed. Our objective was to determine the prev-alence of membranous ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Altmetric